Venture Life Group PLC Board Change (9594Z)

TIDMVLG

RNS Number : 9594Z

Venture Life Group PLC

19 May 2023

19(th) May 2023

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Board change

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announces that Mrs Sharon Daly (nee Collins) will be leaving the Company on 3 August 2023 to pursue

other opportunities   and hence, will cease to be a director . 

Sharon co-founded Venture Life in 2010 and since then, has made a significant contribution to the growth of the business. She has been pivotal in Venture Life's journey of growth over the years, and we would like to thank her for that.

Sharon leaves the business having played a significant role in taking Venture Life from a start up to the substantially bigger business that it is today, listed on AIM.

We would like to express our gratitude and thanks to Sharon for the hard work and support she has given to the business, and wish her the very best in her new endeavours.

Sharon will affect a smooth handover of her responsibilities before she finally leaves the business. At this point, Sharon's role of Chief Commercial Officer will not be replaced on the Board, but her role will be restructured across the existing team within the business, bolstered, if necessary, in due course, with any additional resource identified as needed.

For further information, please contact:

Venture Life Group PLC [phone]

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

Cenkos Securities plc (Nomad and Joint Broker) [phone]

Stephen Keys / Camilla Hume (Corporate Finance)

Russell Kerr / Michael Johnson (Sales)

Singer Capital Markets (Joint Broker)

Shaun Dobson / Alaina Wong (Corporate Finance) [phone]

Jonathan Dighe (Sales)

About Venture Life ( www.venture-life.com )

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAAPMMTMTTBTTJ

(END) Dow Jones Newswires

May 19, 2023 02:00 ET (06:00 GMT)